In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Inmune Bio Inc (INMB), with a price target of $11.50. The company’s shares closed last Monday at $6.14.
Ramakanth observed:
“We maintain our Buy rating of INMB and our 12-month price target of $11.50 per share. We derive our price target based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from 2030, assuming a 13% discount rate and a 0.5% terminal growth rate. We derive an rNPV of $345M for the products and add in cash and cash equivalents of $9.4M to arrive at a 12-month price target of $11.43 per diluted share, which we round to $11.50.”
According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.6% and a 35.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, Corcept Therapeutics Inc, and IntelGenx Technologies.
Inmune Bio Inc has an analyst consensus of Moderate Buy, with a price target consensus of $12.25.
See today’s analyst top recommended stocks >>
Based on Inmune Bio Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $392.1K. In comparison, last year the company had a GAAP net loss of $6.17 million.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INMB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer. Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.
